



Chief Scientific Officer

AC Immune  
Lausanne, Switzerland

## Education & Training

### DOCTOR OF PHILOSOPHY

2001-2005  
Biotechnology  
EPFL - Switzerland

### POSTDOCTORAL RESEARCH FELLOW

2001-2002  
Bacterial vector engineering, Cancer vaccine, Tumor associated antigens screening  
CNRS, Paris - France

### MAITRE ASSISTANTE

2009-2014  
HUG - Genève, Switzerland

### CEO

2012 - 2022  
Amal Therapeutics - Geneva - CH

### CEO

2021 - 2023  
Speransa Therapeutics  
Frankfurt - Germany

### CSO

2024 - Present  
AC Immune  
Lausanne - Switzerland



**MADIHA**

**DEROUAZI**

Biotech Entrepreneur/  
Immunotherapy

## Profile

Dr. Madiha Derouazi holds a PhD in Cellular Biotechnology from EPFL. In 2012, she founded AMAL Therapeutics, an immuno-oncology company developing next-generation cancer vaccines, where she served as both CEO and CSO. Under her leadership, AMAL was acquired by Boehringer Ingelheim. Dr. Derouazi then became CEO of Speransa Therapeutics, where she oversaw the development of a novel platform for prophylactic vaccines. She now serves as Chief Scientific Officer (CSO) at AC Immune.

## Articles

Novel Multi-Antigen Orf-Virus-Derived Vaccine Elicits Protective Anti-SARS-CoV-2 Response in Monovalent and Bivalent Formats.

## Press

“When you're an entrepreneur, you need to do things your way”



[linkedin.com/in/madiha-derouazi](https://www.linkedin.com/in/madiha-derouazi)



[madiha.derouazi@acimmune.com](mailto:madiha.derouazi@acimmune.com)